Literature DB >> 17420451

Analysis of PALB2/FANCN-associated breast cancer families.

Marc Tischkowitz1, Bing Xia, Nelly Sabbaghian, Jorge S Reis-Filho, Nancy Hamel, Guilan Li, Erik H van Beers, Lili Li, Tayma Khalil, Louise A Quenneville, Atilla Omeroglu, Aletta Poll, Pierre Lepage, Nora Wong, Petra M Nederlof, Alan Ashworth, Patricia N Tonin, Steven A Narod, David M Livingston, William D Foulkes.   

Abstract

No more than approximately 30% of hereditary breast cancer has been accounted for by mutations in known genes. Most of these genes, such as BRCA1, BRCA2, TP53, CHEK2, ATM, and FANCJ/BRIP1, function in DNA repair, raising the possibility that germ line mutations in other genes that contribute to this process also predispose to breast cancer. Given its close relationship with BRCA2, PALB2 was sequenced in affected probands from 68 BRCA1/BRCA2-negative breast cancer families of Ashkenazi Jewish, French Canadian, or mixed ethnic descent. The average BRCAPRO score was 0.58. A truncating mutation (229delT) was identified in one family with a strong history of breast cancer (seven breast cancers in three female mutation carriers). This mutation and its associated breast cancers were characterized with another recently reported but unstudied mutation (2521delA) that is also associated with a strong family history of breast cancer. There was no loss of heterozygosity in tumors with either mutation. Moreover, comparative genomic hybridization analysis showed major similarities to that of BRCA2 tumors but with some notable differences, especially loss of 18q, a change that was previously unknown in BRCA2 tumors and less common in sporadic breast cancer. This study supports recent observations that PALB2 mutations are present, albeit not frequently, in breast cancer families. The apparently high penetrance noted in this study suggests that at least some PALB2 mutations are associated with a substantially increased risk for the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17420451      PMCID: PMC1871863          DOI: 10.1073/pnas.0701724104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

Authors:  Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

2.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

Authors:  Bing Xia; Qing Sheng; Koji Nakanishi; Akihiro Ohashi; Jianmin Wu; Nicole Christ; Xinggang Liu; Maria Jasin; Fergus J Couch; David M Livingston
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

3.  Genetic changes in breast cancer detected by comparative genomic hybridisation.

Authors:  R L Loveday; J Greenman; D L Simcox; V Speirs; P J Drew; J R Monson; M J Kerin
Journal:  Int J Cancer       Date:  2000-05-15       Impact factor: 7.396

4.  Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Authors:  Hanne Meijers-Heijboer; Ans van den Ouweland; Jan Klijn; Marijke Wasielewski; Anja de Snoo; Rogier Oldenburg; Antoinette Hollestelle; Mark Houben; Ellen Crepin; Monique van Veghel-Plandsoen; Fons Elstrodt; Cornelia van Duijn; Carina Bartels; Carel Meijers; Mieke Schutte; Lesley McGuffog; Deborah Thompson; Douglas Easton; Nayanta Sodha; Sheila Seal; Rita Barfoot; Jon Mangion; Jenny Chang-Claude; Diana Eccles; Rosalind Eeles; D Gareth Evans; Richard Houlston; Victoria Murday; Steven Narod; Tamara Peretz; Julian Peto; Catherine Phelan; Hong Xiang Zhang; Csilla Szabo; Peter Devilee; David Goldgar; P Andrew Futreal; Katherine L Nathanson; Barbara Weber; Nazneen Rahman; Michael R Stratton
Journal:  Nat Genet       Date:  2002-04-22       Impact factor: 38.330

5.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

Authors:  Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

6.  A recurrent mutation in PALB2 in Finnish cancer families.

Authors:  Hannele Erkko; Bing Xia; Jenni Nikkilä; Johanna Schleutker; Kirsi Syrjäkoski; Arto Mannermaa; Anne Kallioniemi; Katri Pylkäs; Sanna-Maria Karppinen; Katrin Rapakko; Alexander Miron; Qing Sheng; Guilan Li; Henna Mattila; Daphne W Bell; Daniel A Haber; Mervi Grip; Mervi Reiman; Arja Jukkola-Vuorinen; Aki Mustonen; Juha Kere; Lauri A Aaltonen; Veli-Matti Kosma; Vesa Kataja; Ylermi Soini; Ronny I Drapkin; David M Livingston; Robert Winqvist
Journal:  Nature       Date:  2007-02-07       Impact factor: 49.962

7.  Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation.

Authors:  Edurne Arriola; Maryou B K Lambros; Chris Jones; Tim Dexter; Alan Mackay; David S P Tan; Narinder Tamber; Kerry Fenwick; Alan Ashworth; Mitch Dowsett; Jorge S Reis-Filho
Journal:  Lab Invest       Date:  2007-01       Impact factor: 5.662

8.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

9.  Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.

Authors:  Sarah Reid; Detlev Schindler; Helmut Hanenberg; Karen Barker; Sandra Hanks; Reinhard Kalb; Kornelia Neveling; Patrick Kelly; Sheila Seal; Marcel Freund; Melanie Wurm; Sat Dev Batish; Francis P Lach; Sevgi Yetgin; Heidemarie Neitzel; Hany Ariffin; Marc Tischkowitz; Christopher G Mathew; Arleen D Auerbach; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

10.  A genome wide linkage search for breast cancer susceptibility genes.

Authors:  Paula Smith; Lesley McGuffog; Douglas F Easton; Graham J Mann; Gulietta M Pupo; Beth Newman; Georgia Chenevix-Trench; Csilla Szabo; Melissa Southey; Hélène Renard; Fabrice Odefrey; Henry Lynch; Dominique Stoppa-Lyonnet; Fergus Couch; John L Hopper; Graham G Giles; Margaret R E McCredie; Saundra Buys; Irene Andrulis; Ruby Senie; David E Goldgar; Rogier Oldenburg; Karin Kroeze-Jansema; Jaennelle Kraan; Hanne Meijers-Heijboer; Jan G M Klijn; Christi van Asperen; Inge van Leeuwen; Hans F A Vasen; Cees J Cornelisse; Peter Devilee; Linda Baskcomb; Sheila Seal; Rita Barfoot; Jon Mangion; Anita Hall; Sarah Edkins; Elizabeth Rapley; Richard Wooster; Jenny Chang-Claude; Diana Eccles; D Gareth Evans; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Nazneen Rahman; Michael R Stratton
Journal:  Genes Chromosomes Cancer       Date:  2006-07       Impact factor: 5.006

View more
  102 in total

1.  Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.

Authors:  Yuan Chun Ding; Linda Steele; Chih-Jen Kuan; Scott Greilac; Susan L Neuhausen
Journal:  Breast Cancer Res Treat       Date:  2010-10-07       Impact factor: 4.872

2.  Novel germline PALB2 truncating mutations in African American breast cancer patients.

Authors:  Yonglan Zheng; Jing Zhang; Qun Niu; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

3.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

4.  Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.

Authors:  Irene Catucci; Roni Milgrom; Anya Kushnir; Yael Laitman; Shani Paluch-Shimon; Sara Volorio; Filomena Ficarazzi; Loris Bernard; Paolo Radice; Eitan Friedman; Paolo Peterlongo
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

Review 5.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Authors:  Rohit Prakash; Yu Zhang; Weiran Feng; Maria Jasin
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

Review 6.  Fanconi anaemia and the repair of Watson and Crick DNA crosslinks.

Authors:  Molly C Kottemann; Agata Smogorzewska
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

7.  Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.

Authors:  Ciyu Yang; Angela G Arnold; Magan Trottier; Yukio Sonoda; Nadeem R Abu-Rustum; Oliver Zivanovic; Mark E Robson; Zsofia K Stadler; Michael F Walsh; David M Hyman; Kenneth Offit; Liying Zhang
Journal:  Breast Cancer Res Treat       Date:  2016-10-18       Impact factor: 4.872

8.  PALB2 variants in hereditary and unselected Finnish prostate cancer cases.

Authors:  Sanna Pakkanen; Tiina Wahlfors; Sanna Siltanen; Mimmi Patrikainen; Mika P Matikainen; Teuvo L J Tammela; Johanna Schleutker
Journal:  J Negat Results Biomed       Date:  2009-12-15

9.  Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.

Authors:  G Cecener; G Guney Eskiler; U Egeli; B Tunca; A Alemdar; S Gokgoz; I Tasdelen
Journal:  Mol Biol Rep       Date:  2016-08-29       Impact factor: 2.316

Review 10.  Risk of pancreatic cancer in breast cancer families from the breast cancer family registry.

Authors:  Evelina Mocci; Roger L Milne; Elena Yuste Méndez-Villamil; John L Hopper; Esther M John; Irene L Andrulis; Wendy K Chung; Mary Daly; Saundra S Buys; Nuria Malats; David E Goldgar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.